Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

The Psychological Effects of Miscarriage Prediction Score: A Prospective Study (PEMPS)

21. mai 2026 oppdatert av: King's College Hospital NHS Trust
Patients Under 12 Weeks Pregnant With a Single Ongoing Pregnancy Attending the EPU Will be Randomly Assigned to Receive Their Personalised Miscarriage Risk Score or Not. The Study Explores Whether Sharing This Score Affects Anxiety and Whether Patients Find the Information Helpful and Acceptable. (PEMPS)

Studieoversikt

Detaljert beskrivelse

The PEMPS study is a prospective, randomised controlled investigation designed to evaluate the psychological impact of providing individualised miscarriage risk estimates to patients in early pregnancy. The study population comprises individuals attending an Early Pregnancy Unit (EPU) with a confirmed single ongoing intrauterine pregnancy under 12 weeks' gestation. Participants will be randomly allocated in a 1:1 ratio to either receive their personalised miscarriage risk score (intervention group) or to receive standard care without disclosure of such a score (control group).

Randomisation will be implemented using a computer-generated allocation sequence with appropriate allocation concealment to minimize selection bias. The personalised miscarriage risk score will be derived using a validated predictive model incorporating relevant clinical and ultrasound parameters routinely collected during EPU assessment. The methodology underlying the risk calculation will remain consistent across participants to ensure comparability and reproducibility.

Participants in the intervention arm will be provided with their individualised risk estimate in a standardised format, accompanied by a brief explanation to support interpretation. Care will be taken to ensure that the communication approach is clear, non-directive, and does not include additional counselling beyond standard clinical practice. Participants in the control arm will receive routine clinical information and follow-up as per standard EPU protocols, without access to the calculated risk score.

The primary objective of the study is to determine whether disclosure of a personalised miscarriage risk score influences patient-reported anxiety levels in early pregnancy, assessed using a validated questionnaires on Day 0 and Day 7. The secondary objective is patient acceptability of the study using qualitative feedback on Day 7.

Studietype

Intervensjonell

Registrering (Antatt)

372

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

  • Navn: Jackie Ross

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Barn
  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  • Have capacity to understand the study and to provide signed and dated informed consent.
  • Willing to comply with all study procedures and be available for the duration of the study including consenting to follow up of the pregnancy outcome by letter, phone or email according to individual preference.
  • Age 16 years or over
  • Single live ongoing intrauterine pregnancy less than 12 weeks gestation

Exclusion Criteria:

Women with pregnancies of unknown location, ectopic pregnancies or early pregnancy prior to an embryo being seen or an embryo without a heartbeat.

  • Multiple pregnancies
  • Those undergoing assessment or treatment for a psychological condition by a psychiatrist
  • Those who do not speak English or require a translator
  • Women who have taken part in another clinical trial in the last 3 months.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Annen
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Receive Miscarriage Prediction Score
These participants will receive their miscarriage prediction score
Half of the patients will receive a uniquely calculated miscarriage prediction score based on symptoms and individual characteristics
Eksperimentell: Will Not Receive Miscarriage Prediction Score
These patients will not receive a Miscarriage Prediction Score
These patients will not receive a miscarriage prediction score

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
To measure the psychological effects of the miscarriage prediction model
Tidsramme: 7 days

The study will measure patients' psychological wellbeing objectively using a composite psychological distress score. This composite score is derived by combining the Hospital Anxiety and Depression Scale (HADS) and Penn State Worry Questionnaire (PSWQ) scores.

The HADS score has a minimum score of 0 (Low Anxiety/Depression) and maximum score of 42 (High Anxiety/Depression).

The PSWQ has a minimum score of 16 (Low Worry) and a maximum score of 80 (High Worry).

The composite score will therefore have a minimum score of 16 (low psychological distress) and a maximum score of 122 (greater psychological distress).

These questionnaires will be completed on day 0 and day 7 by patients in both treatment arms and a composite score will be calculated.

7 days
To measure the psychological effects of the miscarriage prediction model
Tidsramme: 7 days
The study will measure patients' psychological wellbeing objectively using the Penn State Worry Questionnaire (PSWQ) score. The Penn State Worry Questionnaire has a minimum score of 16 (Low Worry) and a maximum score of 80 (High Worry). This questionnaire will be completed on day 0 and day 7 by patients in both treatment arms.
7 days

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Acceptability of receiving miscarriage prediction score
Tidsramme: 7 days

Acceptability will be assessed by sending patients who receive a miscarriage prediction score the following questions:

  1. Did receiving the miscarriage prediction score help you feel more informed and prepared about your pregnancy outcome? (Yes/No, with an optional text box for further explanation.)
  2. Would you recommend that other women in early pregnancy receive a miscarriage prediction score as part of their care? (Yes/No, with an optional explanation.)
7 days

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Jackie Ross, FRCOG, King's College Hospital NHS Trust

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. juni 2026

Primær fullføring (Antatt)

1. juni 2027

Studiet fullført (Antatt)

1. juni 2028

Datoer for studieregistrering

Først innsendt

16. mars 2026

Først innsendt som oppfylte QC-kriteriene

21. mai 2026

Først lagt ut (Faktiske)

27. mai 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

27. mai 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

21. mai 2026

Sist bekreftet

1. mai 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 356805

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

The investigators do not plan to share IPD. The informed consent obtained from participants and ethics approval does not include provisions for broad data sharing beyond the immediate research team. As such, making IPD available outside the scope of the original study would not align with the consent provided.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere